Xponance Inc. Lowers Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Xponance Inc. lowered its position in Amedisys, Inc. (NASDAQ:AMED) by 14.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 3,735 shares of the health services provider’s stock after selling 614 shares during the period. Xponance Inc.’s holdings in Amedisys were worth $346,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Trexquant Investment LP raised its position in Amedisys by 1,317.8% in the fourth quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider’s stock worth $7,964,000 after acquiring an additional 81,532 shares during the period. Fifth Third Bancorp raised its position in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock worth $32,000 after acquiring an additional 141 shares during the period. Teacher Retirement System of Texas bought a new stake in Amedisys in the first quarter worth about $817,000. Schonfeld Strategic Advisors LLC raised its position in Amedisys by 17.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider’s stock worth $409,000 after acquiring an additional 671 shares during the period. Finally, Deutsche Bank AG raised its position in Amedisys by 22.7% in the fourth quarter. Deutsche Bank AG now owns 2,524 shares of the health services provider’s stock worth $229,000 after acquiring an additional 467 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on AMED. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Wall Street Zen lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 24th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Price Performance

AMED opened at $97.46 on Friday. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of 35.96, a PEG ratio of 1.32 and a beta of 0.94. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $96.01 and a 200-day moving average price of $93.73. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating the consensus estimate of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to analysts’ expectations of $597.43 million. Amedisys had a net margin of 3.79% and a return on equity of 12.52%. Amedisys’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.03 earnings per share. Equities analysts expect that Amedisys, Inc. will post 4.4 EPS for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.